de Yébenes J G, García-Ruiz P J, Sánchez-Pernaute R
Servicio de Neurología, Fundación Jiménez Díaz, Madrid, España.
Rev Neurol. 1997 Sep;25(145):1343-5.
Bromocriptine and pergolide are the two dopamine agonists most often used in Parkinson's disease. Few comparative studies of the efficacy of both compounds are available.
To compare the relative efficacy of bromocriptine and pergolide in patients with Parkinson's disease and intermediate stages of evolution.
Open label study of 5-months of duration. The first agonist was given for two months and, after a period of substitution of one month, the second agonist was also maintained for two months.
Pergolide was more effective than bromocriptine for global scores of the UPDRS, total motor scores, clinical symptoms, akinesia and rigidity. Both compounds were equal effective for the treatment of tremor and fluctuations. Both agonists produced similar side effects.
At the ration 1/10 mg/day pergolide was more effective than bromocriptine in patients with Parkinson's disease at intermediate stages of evolution.
溴隐亭和培高利特是帕金森病中最常使用的两种多巴胺激动剂。关于这两种化合物疗效的比较研究很少。
比较溴隐亭和培高利特在帕金森病中期患者中的相对疗效。
为期5个月的开放标签研究。第一种激动剂给药两个月，经过一个月的替代期后，第二种激动剂也维持给药两个月。
在统一帕金森病评定量表（UPDRS）的总体评分、总运动评分、临床症状、运动不能和强直方面，培高利特比溴隐亭更有效。两种化合物在治疗震颤和症状波动方面效果相当。两种激动剂产生的副作用相似。
在帕金森病中期患者中，每天1/10毫克的培高利特比溴隐亭更有效。
